A股異動丨鳳凰光學(600071.SH)復牌一字漲停 擬進行重大資產重組 轉戰半導體外延材料領域
格隆匯9月30日丨鳳凰光學(600071.SH)復牌一字漲停,報16.94元創逾七個月新高,總市值48億元。鳳凰光學重組方案昨晚揭開“面紗”,此次交易由重大資產出售、發行股份購買資產及募集配套資金三個部分組成。其中,購買資產部分,公司擬向電科材料等發行股份購買國盛電子100%股權;擬向電科材料等發行股份購買普興電子100%股權。如此次重大資產重組順利推進,鳳凰光學將戰略性退出光學器材行業,未來業務將定位於半導體外延材料,主要業務包括半導體外延材料產品的研發、生產以及銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.